Recent studies into retatruptide peptide highlight promising outlook for treating weight and type 2 disease. The molecule, a dual stimulator of GLP-1 and glucose-dependent insulinotropic polypeptide, seems to present improved body mass and blood sugar control compared existing treatments. Ongoing